Oral ibandronic acid inferior to IV zoledronic acid for metastatic breast cancer to bone

Lancet Oncol. 2014 Jan;15(1):114-22. doi: 10.1016/S1470-2045(13)70539-4.

Osteoporosis: Zoledronic acid increases bone mineral density and reduces fracture rate

Asian Pac J Trop Med. 2012 Sep;5(9):743-8. doi: 10.1016/S1995-7645(12)60118-7

Zoledronic acid for postmenopausal osteoporosis reduces fracture risk and improves BMD

J Bone Miner Metab. 2011 May;29(3):328-33. doi: 10.1007/s00774-010-0223-y. Epub 2010 Oct 5

Early vs standard zoledronic acid treatments for prostate cancer metastatic to bone

J Clin Oncol. 2014 Apr 10;32(11):1143-50. doi: 10.1200/JCO.2013.51.6500.

Zoledronic acid reduces early implant migration in total hip arthroplasty

J Bone Joint Surg Am. 2009 Feb;91(2):274-81

WCO-IOF 2016: Denosumab versus zoledronic acid following oral bisphosphonate therapy

Efficacy of zoledronic acid following PLIF in patients with osteoporosis

Osteoporos Int. 2016 Apr;27(4):1469-76

Denosumab noninferior to zoledronic acid in the treatment of bone metastasis

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22

Zoledronic acid increases BMD and prevents fracture risks in women with osteoporosis

J Int Med Res. 2013 Jun;41(3):697-704. doi: 10.1177/0300060513480917. Epub 2013 May 13

Increase in BMD with zoledronic acid in elderly women with osteoporosis and living in LTC

JAMA Intern Med. 2015 Jun;175(6):913-21

Annual infusion of zoledronic acid reduces days of back pain, disability, and bed rest

J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292

Zoledronic acid in the prevention and treatment of glucocorticoid-induced osteoporosis

Lancet. 2009 Apr 11;373(9671):1253-63

Zoledronic acid reduces number of skeletal-related events in new multiple myeloma patients

Lancet Oncol. 2011 Aug;12(8):743-52. doi: 10.1016/S1470-2045(11)70157-7. Epub 2011 Jul 21

Two Infusions of Zoledronic Acid Reduce Femoral BMD Loss after THA Measured over 2 years

J Arthroplasty. 2013 Apr;28(4):671-5. doi: 10.1016/j.arth.2012.08.007. Epub 2012 Nov 8

Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates

J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70

Zoledronic acid reduces rates of new clinical fractures after hip fracture repair

N Engl J Med. 2007 Nov 1;357(18):1799-809. Epub 2007 Sep 17

IV tranexamic acid reduces blood loss and transfusion rate in primary THA

Orthopedics. 2016 Sep 1;39(5):e883-92

Combination of intravenous and topical TXA improves outcomes following primary TKA

J Arthroplasty. 2014 Dec;29(12):2342-6.

Health-related QoL in osteoporotic women improved with zoledronic acid infusions

Bone. 2011 Jun 1;48(6):1298-304. doi: 10.1016/j.bone.2011.03.719. Epub 2011 Mar 21

Intracapsular and intravenous administration for TXA similar in efficacy and safety in TKA

J Arthroplasty. 2016 Nov;31(11):2452-2457